Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Prothena Corporation plc (NASDAQ:PRTA) is among the best NASDAQ stocks under $50 to buy. Roche, a partner of Prothena ...

Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...

Prothena announced partner Roche will advance prasinezumab into Phase III development in early-stage Parkinson’s disease.

Roche has announced that it will be advancing its Prothena-partnered investigational Parkinson’s disease (PD) drug ...

Fintel reports that on May 27, 2025, Oppenheimer downgraded their outlook for Prothena (NasdaqGS:PRTA) from Outperform to Perform. Analyst Price Forecast Suggests 1,057.57% Upside As of May 7, 2025, ...

Prothena would like to thank all of the patients, their families and caregivers, and the investigators, site staff and Prothenians that made this clinical trial possible.” In the Phase 3 AFFIRM ...

Prothena Corporation plc (NASDAQ:PRTA) just the other week announced data from its phase 3 AFFIRM-AL clinical trial using birtamimab for the treatment of patients with AL amyloidosis. The really ...

Prothena has buried birtamimab for the second time. A phase 3 trial of the anti-amyloid antibody in the rare disease AL amyloidosis missed its primary endpoint, prompting the biotech to end ...

DUBLIN - Prothena Corporation plc (NASDAQ:PRTA), currently trading at $6.58, has announced the discontinuation of birtamimab development following the Phase 3 AFFIRM-AL clinical trial results ...

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Incyte (INCY – Research Report), with a price target of $82.00. The company’s shares closed l ...

The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed ...